Join the conversation on Twitter at @UCLAHealth with hashtag #UCLAMDChat Tweets about "#UCLAMDChat"
Welcome to Emmi, our interactive patient education system. For more information >
PET Scan (Positron Emission Tomography)
Prostate Seed Implantation (Permanent Low Dose Rate Brachytherapy)
UCLA Radiation Oncology Patient Education Video – What to expect throughout your treatment
Prostate Health Quiz – This quiz will help you build your knowledge of steps you can take to prevent prostate cancer:
UCLA oncologist Sandy Liu, MD, talked about UCLA’s multi-disciplinary treatment approach to target advanced kidney cancer. The team approaches each case individually with the hope of eradicating all disease with aggressive systemic therapy and, when feasible, adding multi-modal therapy to consolidate residual disease. Watch Video >
Feature on James Michael Tyler, the actor who played sarcastic coffee shop employee Gunther on “Friends”, includes interview with Matthew Rettig, MD, Medical Director, Prostate Cancer Program of the Institute of Urologic Oncology at UCLA and member of the Jonsson Comprehensive Cancer Center. Read the story >
When David McEowen discovered he had a recurrence of prostate cancer, his physicians used PSMA PET as part of his treatment plan. Today, he is cancer-free. The University of California’s two nationally ranked medical centers, UCSF and UCLA are the only two medical centers in the United States that can offer a new imaging technique for prostate cancer - PSMA PET - to the public through FDA approval. A limited number of other U.S. medical centers are currently using PSMA as an investigational technique, generally as part of a clinical trial. However, more hospitals will have the opportunity to adopt the technology after applying for expedited FDA approval, which is now possible as a result of the initial FDA approval gained by UCLA and UCSF. Watch Video >
Medical Director of the Institute of Urologic Oncology Prostate Cancer Program Dr. Matthew Rettig discusses POPCaP and his work involving the health of veterans with prostate cancer and ongoing clinical trials going on exclusively within the Veterans Health Administration (VA) system. The Precision Oncology Program for Cancer of the Prostate (POPCaP), a partnership between the VA and the Prostate Cancer Foundation (PCF) to create a system of excellence for prostate cancer in VA is focused on delivering precision oncology to veterans throughout the United States with a clinical emphasis on advanced prostate cancer. The goal is a development of a molecular biomarker, most likely a genetic sequence through next-generation sequencing, so that a match can be made between a specific genetic lesion and a specific therapy. This genomic sequencing is directing clinicians towards what he calls precision medicine or being able to tailor a specific therapy for that individual person. Watch Video >
A new advance in radiation-therapy equipment is giving physicians the ability to better visualize tumors and internal anatomy, allowing more accurate delivery of necessary treatments. The equipment, called the MRIdian LINAC, is an improvement over older technologies, because it uses a built-in MRI to guide radiation treatment in real time, explains Chief of the Genitourinary Oncology Service at the David Geffen School of Medicine at UCLA and Member of the UCLA Institute of Urologic Oncology Amar U. Kishan, MD. Read More > Watch Video >
Chief of the Genitourinary Oncology Service at the David Geffen School of Medicine at UCLA and Member of the UCLA Institute of Urologic Oncology Amar U. Kishan, MD, tne rationale, logistics and data for stereotactic body radiotherapy for prostate cancer, and how technological advancements have helped to condense treatment schedules. Watch Video >
UCLA urologist Robert Reiter, MD, presented a live-streaming webinar to discuss Ga-PSMA PET CT, a new method for detection and visualization of metastatic prostate cancer not previously visible with conventional and molecular imaging techniques. Ga-PSMA PET CT is now offered at UCLA and aims to improve management of recurrent and high-risk cancers. Watch Video >
Note: Investigational agent. Currently not approved by FDA for imaging prostate cancer.
On Wednesday, April 6, 2016, 11:30 am PST, UCLA urologist Leonard Marks, MD, presented a live-streaming webinar to discuss the benefits of combining the sensitivity of MRI with the convenience of ultrasound to greatly increase accuracy of prostate biopsy. MRI fusion with ultrasound provides the ability to map and target biopsies.
Watch Video >
On Wed, Mar 11, 2015 at 11:30 AM PDT, Allan J. Pantuck, MD, MS, FACS, professor in the UCLA Department of Urology presented a live-streaming webinar to discuss the use of Provenge in the treatment of prostate cancer. Dr. Pantuck discussed the background and rationale for the use of immune-based therapies in the treatment of cancer and the indications, benefits and side effects of Provenge, an FDA-approved treatment for advanced prostate cancer that utilizes the patient’s genetically engineered immune cells. What is Provenge? Provenge Vaccine for Prostate Cancer at UCLA >
Watch Video >
UCLA urologist Robert Reiter, MD - Surgeons increasingly are using robotic surgery to operate on patients, resulting in less blood loss, less pain and faster recovery. Since 2003, UCLA urologic surgeons have performed more than 3,000 procedures robotically to treat prostate, bladder and kidney cancer.
Watch Video >
On April 22, 2015, UCLA urologist, Dr. Mark S. Litwin, presented a live-streaming webinar to discuss common misconceptions about testicular cancer. He also presented an insider’s view of what to do if you have a lump in the testicle or have been told you have testicular cancer.
Watch Video >
Testicular cancer survivor and pro baseball player strives to raise awareness about the condition. UCLA Health Connect for the video story > To learn more about testicular cancer and the UCLA Health team that treats it, visit the UCLA Health Testicular Cancer Program.